{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:16:19Z","timestamp":1776827779020,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s10120-019-00930-2","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T18:54:50Z","timestamp":1550688890000},"page":"988-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients"],"prefix":"10.1007","volume":"22","author":[{"given":"Kotoe","family":"Takayoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakuya","family":"Koreishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Komoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Fukata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-6772","authenticated-orcid":false,"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"930_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https:\/\/doi.org\/10.3322\/caac.21492 .","journal-title":"CA Cancer J Clin"},{"key":"930_CR2","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guideline 2018 (ver.5). Kanehara. 2018"},{"key":"930_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"930_CR4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol"},{"key":"930_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"930_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"930_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"930_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1470-2045(05)70207-2","volume":"6","author":"P Prandoni","year":"2005","unstructured":"Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401\u201310.","journal-title":"Lancet Oncol"},{"key":"930_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejca.2011.11.016","volume":"48","author":"MJ Kang","year":"2012","unstructured":"Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, et al. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer. 2012;48:492\u2013500.","journal-title":"Eur J Cancer"},{"key":"930_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4251\/wjgo.v9.i4.176","volume":"9","author":"K Park","year":"2017","unstructured":"Park K, Ryoo BY, Ryu MH, Park SR, Kang MJ, Kim JH, et al. Incidence of venous thromboembolism and the role of d-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: a prospective study. World J Gastrointest Oncol. 2017;9:176\u201383.","journal-title":"World J Gastrointest Oncol"},{"key":"930_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/jjco\/hyx107","volume":"47","author":"H Arai","year":"2017","unstructured":"Arai H, Hironaka S, Minashi K, Denda T, Shimokawa M, Yamaguchi T. Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer. Jpn J Clin Oncol. 2017;47:942\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"930_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/j.1538-7836.2009.03731.x","volume":"8","author":"KW Lee","year":"2010","unstructured":"Lee KW, Bang SM, Kim S, Lee HJ, Shin DY, Koh Y, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost. 2010;8:540\u20137.","journal-title":"J Thromb Haemost"},{"key":"930_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632\u20134.","journal-title":"J Thromb Haemost"},{"key":"930_CR14","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT S\u00f8rensen","year":"2000","unstructured":"S\u00f8rensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846\u201350.","journal-title":"N Engl J Med"},{"key":"930_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.thromres.2005.10.015","volume":"118","author":"TC Haddad","year":"2006","unstructured":"Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118:555\u201368.","journal-title":"Thromb Res"},{"key":"930_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654\u20136.","journal-title":"J Clin Oncol"},{"key":"930_CR17","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology Cancer-associated venous thromboembolic disease. Version 2. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf"},{"key":"930_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr392","author":"M Mandal\u00e0","year":"2011","unstructured":"Mandal\u00e0 M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011. https:\/\/doi.org\/10.1093\/annonc\/mdr392 .","journal-title":"Ann Oncol"},{"key":"930_CR19","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902\u20137.","journal-title":"Blood"},{"key":"930_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1177\/1076029616668405","volume":"23","author":"JD Ramos","year":"2017","unstructured":"Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, et al. The Khorana score in predicting venous thromboembolism for patients with metastatic urothelial carcinoma and variant histology treated with chemotherapy. Clin Appl Thromb Hemost. 2017;23:755\u201360.","journal-title":"Clin Appl Thromb Hemost"},{"key":"930_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","volume":"150","author":"N Es van","year":"2017","unstructured":"van Es N, Franke VF, Middeldorp S, Wilmink JW, B\u00fcller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30\u20132.","journal-title":"Thromb Res"},{"key":"930_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70018-3","author":"MH Prins","year":"2014","unstructured":"Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014. https:\/\/doi.org\/10.1016\/S2352-3026(14)70018-3 .","journal-title":"Lancet Haematol"},{"key":"930_CR23","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jth.13153","volume":"13","author":"G Agnelli","year":"2015","unstructured":"Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187\u201391.","journal-title":"J Thromb Haemost"},{"key":"930_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615\u201324.","journal-title":"N Engl J Med"},{"key":"930_CR25","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1253\/circj.CJ-88-0010","volume":"75","author":"JCS joint working group","year":"2011","unstructured":"JCS joint working group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75:1258\u201381.","journal-title":"Circ J."},{"key":"930_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"930_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101125","author":"D Diao","year":"2014","unstructured":"Diao D, Wang Z, Cheng Y, Zhang H, Guo Q, Song Y, et al. D-dimer: not just an indicator of venous thrombosis but a predictor of asymptomatic hematogenous metastasis in gastric cancer patients. PLoS One. 2014. https:\/\/doi.org\/10.1371\/journal.pone.0101125 .","journal-title":"PLoS One"},{"key":"930_CR28","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1111\/j.1538-7836.2012.04887.x","volume":"10","author":"MT Stender","year":"2012","unstructured":"Stender MT, Larsen TB, Sorensen HT, Thorlacius-Ussing O. Preoperative plasma d-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost. 2012;10:2027\u201331.","journal-title":"J Thromb Haemost"},{"key":"930_CR29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3324\/haematol.2011.054718","volume":"97","author":"C Ay","year":"2012","unstructured":"Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High d-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97:1158\u201364.","journal-title":"Haematologica"},{"key":"930_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-3043-1","author":"D Diao","year":"2017","unstructured":"Diao D, Cheng Y, Song Y, Zhang H, Zhou Z, Dang C. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. BMC Cancer. 2017. https:\/\/doi.org\/10.1186\/s12885-016-3043-1 .","journal-title":"BMC Cancer"},{"key":"930_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1634\/theoncologist.2015-0284","volume":"21","author":"O K\u00f6nigsbr\u00fcgge","year":"2016","unstructured":"K\u00f6nigsbr\u00fcgge O, Posch F, Riedl J, Reitter EM, Zielinski C, Pabinger I, et al. Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist. 2016;21:252\u20137.","journal-title":"Oncologist"},{"key":"930_CR32","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/j.1538-7836.2010.03948.x","volume":"8","author":"MA Shah","year":"2010","unstructured":"Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost. 2010;8:1702\u20139.","journal-title":"J Thromb Haemost"},{"key":"930_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1160\/TH09-12-0856","volume":"104","author":"AR Folsom","year":"2010","unstructured":"Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost. 2010;104:100\u20134.","journal-title":"Thromb Haemost"},{"key":"930_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/ndt\/gfw227","volume":"32","author":"G Gyamlani","year":"2017","unstructured":"Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32:157\u201364.","journal-title":"Nephrol Dial Transplant"},{"key":"930_CR35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-04-0266","volume":"94","author":"EA Fox","year":"2005","unstructured":"Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005;94:362\u20135.","journal-title":"Thromb Haemost"},{"key":"930_CR36","doi-asserted-by":"publisher","first-page":"e0182997","DOI":"10.1371\/journal.pone.0182997","volume":"12","author":"M Paar","year":"2017","unstructured":"Paar M, Rossmann C, Nusshold C, Wagner T, Schlagenhauf A, Leschnik B, et al. Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One. 2017;12:e0182997. https:\/\/doi.org\/10.1371\/journal.pone.0182997 .","journal-title":"PLoS One"},{"key":"930_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1432-1033.1980.tb04828.x","volume":"109","author":"J Maclouf","year":"1980","unstructured":"Maclouf J, Kindahl H, Granstr\u00f6m E, Samuelsson B. Interactions of prostaglandin H2 and thromboxane A2 with human serum albumin. Eur J Biochem. 1980;109:561\u20136.","journal-title":"Eur J Biochem"},{"key":"930_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/bja\/85.4.599","volume":"85","author":"JP Nicholson","year":"2000","unstructured":"Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599\u2013610.","journal-title":"Br J Anaesth"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10120-019-00930-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-019-00930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-019-00930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T20:28:19Z","timestamp":1694636899000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10120-019-00930-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["930"],"URL":"https:\/\/doi.org\/10.1007\/s10120-019-00930-2","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"6 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M. Kono has received grants from Pfizer Japan Inc. M. Fukata has received grants from Shino-Test Corporation; personal fees from Pfizer, Daiichi Sankyo Company, Bayer Yakuhin, and Boehringer Ingelheim. T. Esaki has received grants and personal fees from Eli Lilly, Taiho, Daiichi-Sankyo, Merck Serono, and Ono; grants from Novartis, DS pharma, MSD and Boehringer; personal fees from Chugai, Bristol, Eisai and Takeda. K. Akashi has received grants and personal fees from Mitsubishi Tanabe Pharma Corporation, Daiichi-Sankyo, MSD, Eisai, Astellas Pharma, Sanofi, Chugai Pharmaceutical, Asahi Kasei Pharma, Kyowa Hakko Kirin, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, Takeda Pharmaceutical, Novartis Pharma, Alexion Pharmaceuticals, Teijin Pharma, Nippon Shinyaku, Yakult Honsha, Mundipharma and Bayer Yakuhin; grants from Ono Pharmaceutical, Merck Serono, Toyama Chemical, Taiho Pharmaceutical, Otsuka Pharmaceutical, Yakult Honsha Co, AbbVie, Shionogi, Eli Lilly Japan, Taisho Toyama Pharmaceutical, Mochida Pharmaceutical, The Chemo-Sero-Therapeutic Research Institute., Merck Serono, Nippon Kayaku, Japan Blood Products Organization, and Shin Nippon Biomedical Laboratories; personal fees from Celgene, Janssen Pharmaceutical, Pfizer, Medical Review, Amgen Astellas Biopharma and Shire Japan. E. Baba has received grants, personal fees and non-financial support from Eli Lilly Japan; grants and personal fees from Daiichi-Sankyo, Bristol-Myers Squibb, Taiho Pharmaceutical. Eisai, Yakult Honsha, and Ono Pharmaceutical; grants from Bayer Yakuhin, MSD, Linical; personal fees from Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Kyowa Hakko Kirin, Sanofi, Merck Serono, Tsumura, Chugai Pharmaceutical, and Astellas Pharma. All of the remaining authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Informed consent or substitute for it was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}